Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Strata Skin Sciences's operating assets for the quarter that ended in Dec. 2025 was €19.31 Mil. Strata Skin Sciences's operating liabilities for the quarter that ended in Dec. 2025 was €9.69 Mil. Strata Skin Sciences's Total Assets for the quarter that ended in Sep. 2025 was €26.17 Mil. Therefore, Strata Skin Sciences's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.37.
Strata Skin Sciences Scaled Net Operating Assets Related Terms
Strata Skin Sciences Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Skin Sciences Scaled Net Operating Assets Chart
FRA:E2O vs ODYY, NUMD, PFSA: Scaled Net Operating Assets Comparison
For the Medical Devices subindustry, Strata Skin Sciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences Scaled Net Operating Assets vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.37 mean?
Strata Skin Sciences (FRA:E2O) has a Scaled Net Operating Assets of 0.37 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Strata Skin Sciences and its competitors.
Is Strata Skin Sciences' Scaled Net Operating Assets too high?
Strata Skin Sciences' current Scaled Net Operating Assets is 0.37. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' Scaled Net Operating Assets compare to ODYY and NUMD?
Strata Skin Sciences' Scaled Net Operating Assets of 0.37 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Devices & Instruments company?
A good Scaled Net Operating Assets depends on the Medical Devices & Instruments industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Strata Skin Sciences and its competitors. Strata Skin Sciences's current Scaled Net Operating Assets is 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current Scaled Net Operating Assets of 0.37. The stock's GF Value™ is €59.29, compared to a current price of €3.76 — trading 93.7% below its estimated fair value. The current Scaled Net Operating Assets is 0.37. Strata Skin Sciences' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current Scaled Net Operating Assets is 0.37 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 93.7% below its estimated GF Value™ of €59.29.
Key valuation signals for FRA:E2O:
Scaled Net Operating Assets: 0.37
GF Value™: €59.29 vs. price of €3.76 (93.7% below fair value)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
